Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer
- 1 January 1993
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 32 (5) , 396-398
- https://doi.org/10.1007/bf00735926
Abstract
An estrogen receptor-negative, multidrug-resistant MDA-MB-A1 human breast cancer cell line was grown in culture with and without a noninhibitory concentration (0.5 μM) of tamoxifen for 122 days. Tamoxifentreated and control cells were inoculated into opposite flanks of nine nude mice, where they produced measurable tumors in every case. Six of the animals were treated with tamoxifen at 500 μg/day for 22 days. Although no inhibitory nor stimulatory effect of tamoxifen was seen in vitro, tamoxifen had a clear tumor-growth-stimulating effect in mice. The most pronounced stimulatory effects were observed in the cells that had been cultured with tamoxifen. Within 3 weeks of the start of tamoxifen therapy, the cells grown in the presence of tamoxifen produced tumors with a mean size of 380 mm2, whereas the cells not pretreated with tamoxifen had tumors of 220 mm2. In contrast, in mice not receiving tamoxifen, the sizes of the tumors were 190 and 140 mm2, respectively. These preliminary results suggest that prolonged in vitro tamoxifen exposure induces cellular changes that result in tumors that are stimulated to grow faster in mice following tamoxifen treatment.Keywords
This publication has 10 references indexed in Scilit:
- Tamoxifen QuandaryScience News, 1992
- Overview From the International Conference on Long-Term Tamoxifen Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 1992
- Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cellsBreast Cancer Research and Treatment, 1992
- Incidence of New Primary Cancers After Adjuvant Tamoxifen Therapy and Radiotherapy for Early Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Clinical Relevance of Immunohistochemical Detection of Multidrug Resistance P-Glycoprotein in Breast CarcinomaJNCI Journal of the National Cancer Institute, 1991
- ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERSThe Lancet, 1989
- TAMOXIFEN AS RISK FACTOR FOR CARCINOMA OF CORPUS UTERIThe Lancet, 1988
- Project of Experimental Bioassays on Chemoprevention Agents Performed at the Bologna Institute of Oncology: Report on Tamoxifen Control of Spontaneous Mammary Tumors on Sprague-Dawley RatsCancer Investigation, 1988
- The pharmacology and clinical uses of tamoxifenPharmacology & Therapeutics, 1984
- Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.The Journal of cell biology, 1975